Powers Principal William von Oehsen recently co-wrote an editorial discussing drug purchasing strategies that could be used to treat people with Hepatitis C within the criminal justice system.

The editorial, which appears in the May edition of the American Journal of Public Health, discusses why drug manufacturers are disincentivized to offer better pricing on direct-acting antiviral agents and how correctional institutions can overcome the pricing challenges to combat Hepatitis C infections.  In particular, it recommends that correctional facilities partner with hospitals and clinics participating in the 340B drug discount program or with state Medicaid agencies interested in seeking federal waiver authority to engage in bulk purchasing.

Bill published the article with co-authors Matthew Akiyama of Albert Einstein College of Medicine/Montefiore Medical Center; Rich Feffer of Hepatitis Education Project; and Alain H. Litwin of the Department of Medicine, Greenville Health System.

To read the full editorial, click here.

William von Oehsen has extensive experience in general health law, legislation and policy, especially in the areas of pharmaceutical pricing, food and drug law, materials management, managed care and third party reimbursement.

Bill has more than 20 years of experience on pharmaceutical pricing and reimbursement matters, including the 340B drug discount program, the Medicaid drug rebate program, Medicare Part D, Robinson-Patman, and state Medicaid and pharmacy laws.

In addition to representing safety-net providers participating in the 340B program, Bill provides guidance to pharmacies, pharmacy-related vendors and consultants, states, local governments, and other healthcare entities in their efforts to improve access to pharmaceutical care and to ensure compliance with drug pricing laws.

For more information regarding the drug pricing or the 340B program, contact Bill von Oehsen at 202-872-6765 or William.vonOehsen@powerslaw.com.

Leave a Reply